A Multicenter Observational Cohort Study of Angiotensin II in Shock.

ABSTRACT:

Introduction

Angiotensin II (Ang-2) is a non-catecholamine vasopressor that targets the renin-angiotensin-aldosterone system by agonism of the angiotensin type 1 receptor. Its utility as a vasopressor and a catecholamine-sparing agent was demonstrated in the pivotal ATHOS-3 trial, and numerous post-hoc analyses have shown reduced mortality in certain subsets of the population.

Methods

Consecutive adult patients at 5 centers who received Ang-2 from 2017-2020 were included in this multicenter, retrospective observational cohort study. Patient demographics, hemodynamics, and adverse events were collected. The primary outcomes of the study were the mean difference in MAP and norepinephrine (NEpi)-equivalent dose at hours 0 and 3 following initiation of Ang-2 therapy.

Results<

SUBMITTER: Smith SE 

PROVIDER: S-EPMC8559525 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature